Protagonist Therapeutics, Inc.

( )
PTGX After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
AMGNAmgen Inc.
CELGCelgene Corporation
GILDGilead Sciences, Inc.
BIIBBiogen Inc.
NKTRNektar Therapeutics
REGNRegeneron Pharmaceuticals, Inc.
VRTXVertex Pharmaceuticals Incorporated
ALXNAlexion Pharmaceuticals, Inc.
ILMNIllumina, Inc.
AAgilent Technologies, Inc.
EXASExact Sciences Corporation
INCYIncyte Corporation
BLUEBluebird Bio, Inc.
SRPTSarepta Therapeutics, Inc.
BMRNBioMarin Pharmaceutical Inc.

Company Profile

Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which offers proprietary peptide technology platform, which discovers and develops new chemical entities to address significant unmet medical needs. The firm's initial lead product candidates, PTG-100 and PTG-200, is being developed for moderate-to-severe ulcerative colitis and Crohn's disease, respectively. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Milpitas, CA.